Drug licenses: A new model for pharmaceutical pricing
Drug licenses: A new model for pharmaceutical pricing
复制标题
DOI：
10.1377/hlthaff.27.1.122
复制
发表时间：
2008-01-01
期刊：
影响因子：
9.7
通讯作者：
Sun, Eric
中科院分区：
文献类型：
--
作者：
Goldman, Dana P.;Jena, Anupam B.;Sun, Eric
High drug prices are a major barrier to patients' access to drugs and compliance with treatment. Yet low drug prices are often argued to provide inadequate incentives for innovation. We propose a drug-licensing model for health care, which has the promise of increasing drug use without altering patients' out-of-pocket spending, health plans' costs, or drug companies' profits. In such a model, people would purchase annual drug licenses that would guarantee unfettered access to a clinically optimal number of prescriptions over the course of a year. Using the example of statins, we illustrate how such a model could be implemented.
